Research · 1 min read
BPC-157 Research: Evidence and Limits
What animal studies report about BPC-157, where human evidence is limited, and how to read the findings.
By the Compound Lab editorial teamPublished
Where the evidence comes from
The majority of BPC-157 literature originates from a small number of research groups using rat models. Endpoints include tendon-to-bone healing, gastric lesion size and angiogenesis markers.
Because so much of the work comes from closely connected groups, independent replication is one of the most important things to look for when weighing a result.
What is not known
There are few published randomised human studies. Pharmacokinetics, optimal handling and long-term effects remain open research questions.
Animal findings do not automatically translate to people: dose scaling, route of administration and study duration all differ from any human setting.
Reading the studies
Look for replication across independent labs, clear dosing in mg/kg, adequate control groups and whether results are histological (tissue appearance) or functional (strength, movement, healing time).
Check whether the compound used was characterised: a study is only as reliable as the identity and purity of the material it tested.
Continue with
Sources and evidence
- 01BPC 157 — indexed publications (opens in a new tab)PubMed, U.S. National Library of Medicine
- 02BPC 157 and standard angiogenic growth factors: gastrointestinal tract healing, lessons from tendon, ligament, muscle and bone healing (opens in a new tab)Curr Pharm Des 2018 (Seiwerth et al.)
Sources compiled for this concept; Compound Lab's editorial team should review them before launch.
For laboratory research reference only. This article is not medical advice.